

## 2016-2017 American Heart Association Support from Pharmaceutical Companies and Device Manufacturers

We value the trust placed in us by our donors, supporters and the general public, and we feel the best way to continue to earn that trust is to make the association's finances as transparent as possible. In fact, the American Heart Association has consistently met the high standards of the [Better Business Bureau's Wise Giving Alliance \(WGA\)](#), the premier organization evaluating charitable organizations.


Most of the revenue recorded by the American Heart Association comes from sources other than corporations. These sources include contributions from individuals, foundations and estates as well as investment earnings and revenue from the sale of educational materials.

Financial support from corporations helps the association's programs and campaigns more effectively achieve our goals of improving the cardiovascular health of all Americans and saving more lives. All corporate relationships are required to comply with the association's corporate relations policies, and regional and national corporate relationships are approved by a committee of national volunteers and executive staff.

Total corporate support is comprised of unrestricted gifts and special event and program sponsorships, and includes support committed to the entire American Heart Association, including National Center, its Affiliates and local offices. It represents approximately 20.0 percent of the AHA's \$911,987,000 in total revenue (2016-2017 audited financial statements).

Support that the American Heart Association receives from pharmaceutical companies, device manufacturers and health insurance providers is included within total corporate support and represents approximately 1.6 percent of the association's total revenue. The majority of funding from these sources occurs at the national level.

The revenue figures below include the total amount of funds committed during fiscal year 2016-2017, noting that, in some cases, the funds will be received in future years.



NOTE: The Pie Chart above shows income committed in fiscal year 2016-2017 to the American Heart Association from pharmaceutical companies, device manufacturers, biotech companies and health insurance providers and the amount of total corporate support committed to AHA association-wide, compared to all sources of revenue.

Listed below in the middle column is cash received by the American Heart Association from pharmaceutical companies, device manufacturers, biotech companies and health insurance providers during fiscal year 2016-2017.

In addition, the right column reflects revenue that was committed to the American Heart Association during fiscal year 2016-2017, but will be received in future years. An example is a multi-year sponsorship of an American Heart Association program or campaign.

FY 2016-2017 Contributed Income and Other Revenue Raised at the National Level from Pharmaceutical Companies and Medical Device Manufacturers		
Corporation	Total Cash Received During FY 2016-2017 on Prior and Current Year Commitments (1)	Current Year FY 2016-2017 Commitments Receivable in the Future
3M	-	320,000
Allergan	65,000	-
Amarin	-	220,000
Amgen	2,120,000	-
Anthem	1,292,213	-
Aralez Pharmaceuticals	115,000	705,000
Arthrex	100,000	-
Assurance	-	125,000
AstraZeneca	150,000	-
Bayer Crop Science	-	400,000
Bayer Healthcare	552,000	1,859,000
Biotronik, Inc.	62,500	-
BMS/Pfizer	846,000	-
Boehringer Ingelheim Pharmaceuticals	256,667	231,750
Boston Scientific	130,000	-
Carefirst BlueCross BlueShield	56,250	-
Chiesi	35,000	-
Daiichi Sankyo	115,000	-
Edwards Lifesciences LLC	700,000	-
Genentech	165,810	-
Gilead Sciences	474,343	84,775
GlaxoSmithKline	25,000	-
Janssen	590,000	160,000
Kaiser Permanente	2,600,000	-
Laerdal Medical Corporation	615,000	-
Lundbeck	30,000	-
Medpace	125,000	-
MedThink (Arbor Pharmaceutical)	7,500	-
Medtronic/Covidien/EV3	3,160,503	2,407,500
Merck	137,500	-
MyoKardia	25,000	-
Nephron Pharmaceuticals	-	300,000
NICO	25,000	-
Novartis Pharmaceuticals	4,437,798	910,000
NovoNordisk	-	140,000
Pfizer	970,000	90,000
Philips Healthcare	315,000	275,000
Physio-Control	30,000	15,000
Relypsa	145,000	-
Sanofi	493,000	295,000
Sanofi-Regeneron	1,300,000	-
SciEx	-	1,500
SomaLogic, Inc.	5,000	-
Stryker Neurovascular	40,700	-
Transamerica	500,000	-
Verily (Google Life Science)	1,000,000	-
WorldPoint	37,500	-
Zoll Medical	15,000	-
<b>Totals</b>	<b>23,865,284</b>	<b>8,539,525</b>

NOTE: (1) Reflects all corporate contributions to National Center and 10 highest corporate contributions to each Affiliate. Column includes cash received on commitments from contracts and conferences. This was recorded as revenue in FY 2012-13 through FY 2016-17.